Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 2Gynecologic 2Gastrointestinal 2Dermatologic 2Breast 2Head & Neck 1Endocrine 1CNS 1

Conditions

Small Cell Lung Carcinoma 1Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 4atezolizumab 2Topotecan 2Paclitaxel 2Nivolumab 2Etoposide 2veliparib 1tocilizumab 1tislelizumab 1temsirolimus 1surufatinib 1sargramostim 1pentetreotide 1pembrolizumab 1niraparib 1iadademstat 1entinostat 1durvalumab 1dostarlimab 1cabozantinib 1budigalimab 1berzosertib 1belinostat 1aldesleukin 1Vinorelbine 1Temozolomide 1Specimen Handling 1Sirolimus 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Small Cell Lung Carcinoma × budigalimab × Endocrine × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡